Radionuclide bone scan in patients with newly diagnosed prostate cancer. Clinical aspects and cost analysis;Die skelettszintigraphie beim neu diagnostizierten prostatakarzinom. Klinische aspekte und kostenanalyse

Urologe - Ausgabe A

Volumn 45, Issue 10, 2006, Pages 1293-1299

  Klatte, T ^a,c   Klatte, D ^a   Bohm M ^b   Allhoff, E P ^c  

^a Urologische Gemeinschaftspraxis   (Germany)

^b Otto von Guericke Universität ^*  (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Bone metastasis; Bone scan; Guidelines; Prostate cancer; PSA

Indexed keywords

ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER STAGING; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; HEALTH CARE COST; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RETROSPECTIVE STUDY;

BONE NEOPLASMS; COST-BENEFIT ANALYSIS; GERMANY; HEALTH CARE COSTS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIONUCLIDE IMAGING; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 33750289045     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-006-1078-7     Document Type: Article

References (38)

1. Arbeitsgemeinschaft bevölkerungsbezogener Krebsregister in Deutschland (2004) Krebs in Deutschland. Arbeitsgemeinschaft bevölkerungsbezogener Krebsregister in Deutschland, Saarbrücken, S 9
2. Aus G, Abbou CC, Bolla M et al. (2005) EAU guidelines on prostate cancer. Eur Urol 48: 546-551
3. Aus G, Abbou CC, Pacik D et al. (2001) EAU guidelines on prostate cancer. Eur Urol 40: 97-101
4. Ball JD, Maynard CD (1979) Nuclear imaging in urology. Urol Clin North Am 6: 321-342
5. Bartsch G, Horninger W, Klocker H et al. (2001) Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58: 417-424
6. Batson OV (1940) The function of the vertebral veins and their role in the spread of metastases. Ann Surg 112: 138-149
7. Carlin BI, Andriole GL (2000) The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88: 2989-2994
8. Charhon SA, Chapuy MC, Delvin EE et al. (1983) Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 51: 918-924
9. Cher ML (2001) Mechanisms governing bone metastasis in prostate cancer. Curr Opin Urol 11: 483-488
10. Chodak G, Iversen P, McLeod D et al. (2005) Prostate-specific antigen levels as a predictor of positive bone scans during follow-up after standard care for prostate cancer: data from the bicalutamide early prostate cancer program. J Urol 173(Suppl): 275
11. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE (1991) Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 145: 313-318
12. Constable AR, Cranage RW (1981) Recognition of the superscan in prostatic bone scintigraphy. Br J Radiol 54: 122-125
13. Crawford ED, Eisenberger MA, McLeod DG et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424
14. Deutsche Gesellschaft für Urologie (1999) Guidelines for diagnosis of prostate carcinomas. Urologe A 38: 389-401
15. Gerber G, Chodak GW (1991) Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. Urology 37: 418-422
16. Hankey BF, Feuer EJ, Clegg LX et al. (1999) Cancer surveillance series: interpreting trends in prostate cancer, part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91: 1017-1024
17. Ishizuka O, Tanabe T, Nakayama T et al. (2005) Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan. Int J Urol 12: 728-732
18. Jemal A, Murray T, Ward E et al. (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10-30
19. Jørgensen T, Müller C, Kaalhus O et al. (1995) Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Experience from the Scandinavian Prostatic Cancer Group Study No. 2 (SPCG-2). Eur Urol 28: 40-46
20. Kemp PM, Maguire GA, Bird NJ (1997) Which patients with prostatic carcinoma require a staging bone scan? Br J Urol 79: 611-614
21. Lee CT, Oesterling JE (1997) Using prostate-specific antigen to eliminate the staging radionuclide bone scan. Urol Clin North Am 24: 389-394
22. Lin K, Szabo Z, Chin BB, Civelek AC (1999) The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med 24: 579-582
23. McGregor B, Tulloch AG, Quinlan MF, Lovegrove F (1978) The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol 50: 178-181
24. Middleton RG, Thompson IM, Austenfeld MS et al. (1995) Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol 154: 2144-2148
25. National Cancer Institute (2005) SEER Database,http://www.seer.cancer.gov (Zugriff: 30.11.2005, 13:15 MEZ)
26. National Center for Health Statistics (2004) Health, United States, 2004, with Chartbook on Trends in the Health of Americans. Hyattsville, Maryland, pp 209-212
27. National Comprehensive Cancer Network (NCCN) (2005),http://www.nccn.org (Zugriff: 30.11.2005, 12:00 MEZ)
28. O'Donoghue EP, Constable AR, Sherwood T et al. (1978) Bone scanning and plasma phosphatases in carcinoma of the prostate. Br J Urol 50: 172-177
29. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC (1993) The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269: 57-60
30. Potosky AL, Miller BA, Albertsen PC, Kramer BS (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273: 548-552
31. Rigaud J, Tiguert R, Le Normand L et al. (2002) Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol 168: 1423-1426
32. Robert-Koch-Institut (2005)http://www.rki.de (Zugriff: 30.11.2005, 13:00 MEZ)
33. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664
34. Schaffer DL, Pendergrass HP (1976) Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 121: 431-434
35. Soloway MS, Hardeman SW, Hickey D et al. (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202
36. Terris MK, Klonecke AS, McDougall IR, Stamey TA (1991) Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 32: 1713-1717
37. Wolff JM, Bares R, Jung PK et al. (1996) Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Urol Int 56: 169-173
38. Wolff JM, Zimny M, Borchers H et al. (1998) Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 33: 376-381